

Index

- ABCC6 gene mutations, 132–133
 ABCD2 score, 61, 576–577
 ABCD3-I score, 576
 abciximab, 165, 179
 Abciximab in Emergent Stroke Treatment Trial II (AbESTT-II), 179
 abdominal imaging, 579
 Abercrombie, John, 4, 544
 AbESTT trials, 165
 acetazolamide, 168
 Ackerman, Robert, 6
 activated partial thromboplastin time (aPTT), 112
 activity-based brain repair therapies, 613
 acute posterior, multifocal, placoid-pigment epitheliopathy, 406
 Adams, Raymond, 6
 AIDS, 394, 398
 arteriopathy associated with, 399
 air embolism, 349–350
 Alberta Stroke Program Early CT Score (ASPECTS), 81
 alcohol use
 risk factor for stroke, 575
 ALDH2 gene, 137–138
 alexia without agraphia, 276
 Alzheimer's disease, 104, 135, 396, 579
 amantidine, 615
 Amarenco, Pierre, 336
 amaurosis fugax, 218, 231
 ambulatory cardiac rhythm monitoring, 7
 amebic infections of the CNS, 400
 amphetamine, 189, 408, 482
 ICH related to, 484–485
 therapeutic use, 615
 Amplatzer PFO Occluder, 173, 336
 anatomy of stroke, 19
 cervico-cranial artery walls, 31
 common locations for ICH, 41
 common sites of intracranial aneurysms, 38–39
 distribution of brain pathology, 39–41
 distribution of embolic pathology, 38
 distribution of ICH pathology, 38
 distribution of ischemic pathology, 39–40
 distribution of SAH pathology, 38–39
 distribution of thrombosis pathology, 36–38
 distribution of vascular pathology, 36–39
 importance of identifying the location, 25–26
 normal arterial circulation, 26–31
 venous and dural sinus anatomy, 31–34
 aneurysm
 ancrod, 112, 160, 168
 anemia, 170, 415, 546
 anemic-hypoxic brain injury, 365
 common sites of intracranial aneurysms, 38–39
 treatment of unruptured aneurysms, 454
 aneurysmal SAH
 antifibrinolytic agents, 452
 blood pressure control, 452
 cardiac and pulmonary abnormalities, 451
 causes, 439
 causes of rupture, 440
 clinical findings, 441–443
 clinical severity scales, 443
 complications and their management, 447–452
 consequences of aneurysm rupture, 439
 delayed cerebral ischemia (vasoconstriction), 448–450
 diagnostic testing, 443–446
 computed tomography (CT), 443–444
 CT perfusion scanning, 446
 diffusion and perfusion MR scanning, 446
 digital subtraction cerebral angiography, 445–446
 lumbar puncture, 445
 magnetic resonance imaging (MRI), 444–445
 SPECT, 446
 transcranial Doppler ultrasound (TCD), 446
 xenon-enhanced CT, 446
 differential diagnosis, 446
 endocrine abnormalities, 451–452
 endovascular treatment of aneurysms, 452–454
 familial occurrence of aneurysms, 440
 fluid and electrolyte abnormalities, 451
 giant aneurysms, 440
 headache, 441
 hydrocephalus, 450–451
 importance of early diagnosis, 440
 locations of saccular aneurysms, 439–440
 microsurgical treatment of aneurysms, 452–454
 multiple aneurysms, 440
 mycotic aneurysms, 454
 neurological symptoms and signs, 441–443
 obliteration of aneurysms, 452–454
 pathogenesis of aneurysms, 440
 rebleeding (hemorrhage), 448
 risk factors for aneurysms, 440
 risk of aneurysm rupture, 439
 sentinel headache, 441
 supportive critical care medicine, 450
 symptoms, 439
 treatment of unruptured aneurysms, 454
 angitis
 as cause of stroke, 396
 angiography, 7
 angioplasty and/or stenting, 151–154, 161, 217
 anterior cerebral arteries (ACA), 26–28
 caudate nucleus infarcts, 241–243
 intracranial dissections, 390
 occlusion or severe stenosis, 239–241
 anterior choroidal arteries (AChA), 27–28
 occlusion, 243–244
 anterior circulation, 28
 large artery occlusive disease, 217–244
 anterior inferior cerebellar artery (AICA), 31
 anticardiolipin antibody, 113
 anticoagulants, 170–177
 arterial dissection, 174–176
 aspirin, 9
 bleeding disorders associated with, 115
 cardiac-origin embolism, 172–174
 cerebral venous thrombosis, 174
 development of therapies, 9
 dural sinus thrombosis, 174
 factor Xa inhibitors, 176–177
 heparin, 170–171
 in non-cardioembolic strokes, 174–176
 indications and timing, 172–176
 large artery thrombosis, 174–176
 sites of hemorrhage, 41
 thrombin inhibitors, 176–177
 warfarin, 172
 antiphospholipid antibodies (APLAs), 113
 antiphospholipid antibody (APLA) syndrome, 111, 113, 329–331, 416–417, 546
 antiplatelet agents, 169
 aspirin, 9
 antiplatelet therapies for specific vessel sites, 180
 antipsychotic drugs, 338
 antithrombin, 112
 antithrombin deficiency, 416
 antithrombin III, 45
 Anton's syndrome, 276–277
 aorta
 source of brain emboli, 336–337

Index

- Aortic Arch Related Cerebral Hazard (AARCH) trial, 180, 337
- aortic conditions
 risk of stroke, 580
- aortic regurgitation, 324
- aortic valve disease
 source of brain emboli, 323–324
- aphasia
 therapies for, 617
- apixaban, 9, 176, 177, 321
- APOE* gene, 137, 139
- apoplexy, 2
- apoptosis, 43
- APP* gene mutation, 135
- apraxia of gaze, 278
- acquired hemophilia, 416
- argatroban, 165, 176
- ARISTOTLE trial, 321
- arterial circulation
 normal circulation, 26–31
- arterial dissections, 37–38, 386
 anticoagulant indications and timing, 174–176
 carotid artery dissections in the neck, 386–389
 intracranial dissections, 390
 management, 390–391
 vertebral artery dissections in the neck, 389–390
- arterial sources of brain emboli, 341–342
- arteries
 composition of cervico-cranial artery walls, 31
 morphology of extracranial arteries, 31
 morphology of intracranial arteries, 31
- arteriovenous malformations (AVMs), 454–455
 clinical symptoms and signs, 458–460
 diagnosis, 460
 imaging findings, 460
 locations, 458
 pathogenesis, 456–457
 prognosis, 461
 treatment, 462–464
- arteritis, 20
 as cause of stroke, 396
 bacterial infections, 397–399
 caused by infections, 397–400
 fungal infections, 397–399
 parasitic infections, 400
 viral infections, 399–400
- Aspergillus* infection, 398–399, 551
- aspiration
 complication in stroke patients, 599–600
- aspirin, 165, 169, 177
 anticoagulant properties, 9
- Asymptomatic Carotid Artery Study, 228
- ataxic hemiparesis, 293
- Athens Stroke Registry, 279–280
- atherosclerosis, 20
 sites of atherosclerotic narrowing, 36–37
- atherosclerotic plaques, 8, 43–44
- atherothrombosis, 45
- atlases published in the nineteenth century, 4
- atorvastatin, 183, 184, 568
- ATP7A* gene mutation, 419
- atrial fibrillation, 171, 172–173
 risk of brain embolism, 318–322
- atrial septal aneurysm (ASA), 335
- atrial septal defects, 20, 173–174
 source of brain emboli, 333–336
- atromid, 169
- autosomal dominant type 1 porencephaly, 135
- AX200 for Ischemic Stroke (AXIS) study, 616
- Axenfeld–Rieger syndrome, 136
- B19 virus, 399
- Babikian, Viken, 6
- bacterial causes of vasculitis, 397–399
- bacterial endocarditis, 173, 579
- Balint's syndrome, 278, 372–373
- balloon angioplasty, 12–13, 151, 153
- balloon catheterization, 12
- Baltimore–Washington Young Stroke Study, 526
- Barnett, Henry, 10
- Baron, Jean-Claude, 6
- Bartleson's syndrome, 410
- Bartonella henselae* infection, 398, 399
- basic fibroblastic growth factor (bFGF), 616
- BASICS Registry, 270
- basilar arteries, 28–31
 bilateral brainstem infarction, 266–273
 dissection of the basilar artery, 273
 intracranial dissections, 390
 unilateral brainstem infarction, 273
 vasculitis, 400
- Basilar Artery International Cooperation Study (BASICS), 270
- Bayes' theorem, 56–57
- bedside tests of high-level cortical function, 71
- Behçet's disease, 405, 546
- Besancon Stroke Registry, 279–280
- beta-hCG+erythropoietin in acute stroke (BETAS) study, 616
- beta-human chorionic gonadotropin (hCG), 616
- Binswanger's disease, 301, 302
- biomarkers for vascular disease, 580–581
- bleeding diatheses, 24
- bleeding disorders, 416
 hereditary, 115
 iatrogenic, 115
- blood abnormalities
 in intracerebral hemorrhage, 115
 in subarachnoid hemorrhage, 115
 role in stroke, 110
- blood abnormalities in ischemic stroke, 110–114
 additional blood measurements, 113–114
 albumin and globulin levels, 112
 antiphospholipid antibodies (APLAs), 113
 blood sugar levels, 113
 blood viscosity, 111–112
 coagulation factors, 112–113
 coagulation testing, 112–113
 erythrocytes, 110–111
 fibrinogen, 111–112
 leukocytes, 111
 lipoprotein levels, 112
 platelets, 111
 testing that reflects stroke risk, 114
- blood flow disorders, 416–417
- blood sugar levels, 113
- blood viscosity, 111–112
 disorders, 416–417
 reduction, 168–169
- Blumgart, Dr Herman, 2
- body-weight supported treadmill training (BWSTT), 613
- borderzone infarcts and hemodynamic impairment, 372–373
- borderzone regions, 22, 39–40
 spinal cord, 535
- Borrelia* infection, 398
- Boston Stroke Society, 6
- Boyle, Robert, 3
- bradycardia-tachycardia syndrome, 322
- brain
 autoregulation of cerebral blood flow, 42
 energy and oxygen requirements, 41–42
 increasing resistance to ischemia, 181–183
 normal metabolism and blood flow, 41–42
- brain-derived neurotrophic factor (BDNF), 616
- brain edema
 causes, 184
 complications in stroke patients, 595–596
 effects of, 184
 management, 346
 reducing or limiting the size of ICH, 184–186
 related to brain infarct, 84
- thrombosis pathophysiology, 47
- treatment, 186–188
- brain embolism
 clinical findings related to the recipient artery, 312–314
 imaging related to the recipient artery, 315–318
 laboratory findings related to the recipient artery, 315–318
 likelihood of causing stroke and infarction, 312
 occurrence of embolic particles, 312
 See also embolism.
- brain embolism treatment
 antithrombotic treatment, 345
 augmenting brain blood flow, 345
 chemical or mechanical clot removal, 344
 goals of, 343
 neuroprotection, 345
 opening of blocked recipient arteries, 343–344
 reperfusion, 343–345
 thrombolysis, 344
 treatment strategies, 343
- brain embolus sources
 air embolism, 349–350
 aorta, 336–337
 aortic valve disease, 323–324
 arrhythmias, 318–322
 arterial sources, 341–342
 atrial fibrillation, 318–322
 cardiac septal lesions, 333–336
 cardiac sources, 318–336
 cardiac surgery complications, 338–341
 cardiac tumors, 332–333
 cardiac valve disease, 322–326
 cardiac valve strands, 328–331
 coronary artery disease, 331–332
 fat embolism, 347–349
 foreign body embolism, 350–351
 imaging of potential donor sources, 342–343
 infective endocarditis, 326–328
 laboratory evaluation of potential donor sources, 342–343
 materials that originate outside the vascular system, 347–351
 mitral annulus calcification (MAC), 325
 mitral valve prolapse (MVP), 324–325
 myocardial infarction, 331–332
 myocardiopathies, 332

Index

- non-infective fibrous and
fibrinous endocardial
lesions, 328–331
paradoxical embolism,
333–336
patent foramen ovale,
333–336
prosthetic cardiac valves,
325–326
range of sources, 318
rheumatic mitral valve
disease, 322–323
sick sinus syndrome, 322
sinus node dysfunction, 322
tumor embolism, 350
types of embolic materials,
318
brain embolus treatment
brain edema management, 346
chronic prophylactic
treatment to prevent
reembolization, 346–347
mass effect management, 346
brain function
EEG (electroencephalogra-
phy), 115
brain lesion investigation, 82–83
infarcts, 83–84
brain-machine computer
interfaces, 190
brain repair strategies
activity-based therapies, 613
brain stimulation therapies,
614–615
cognitive strategies, 617
emerging neural repair
strategies, 613
for aphasia, 617
for cognitive deficits, 617
for visual field defects, 617
gait training, 72
growth factors, 616
mental activity, 617
movement observation, 617
pharmacological therapies,
615
principles of brain repair,
617–618
robot-based therapies,
613–614
sensory stimulation, 614
stem cell therapies, 615–616
telerehabilitation, 614
brain shifts caused by mass
effects, 48–49
brain small vessel disease
with Axenfeld-Rieger
anomaly, 135
brain small vessel disease with
hemorrhage, 135
brain stimulation therapies,
614–615
brainstem
bilateral infarction, 266–273
unilateral infarction, 273
branch artery disease. *See* lacunar
infarction; lacunar
stroke
brightness modulation
(B-mode) ultrasound,
87–88
Bright's atlas, 4
bromocriptine, 189, 615
Bruckmann, Helmut, 11
Buerger's disease, 404
CADISP consortium, 138
calcarine bank lesions, 277–279
calcific aortic stenosis, 173
calcium channel blockers, 168
California encephalitis virus,
399
Canadian–American
Ticlopidine Study
(CATS), 178
Canadian Pediatric Ischemic
Stroke Registry, 513
cancer
and cerebral venous throm-
bosis (CVT), 545–546
stroke related to, 416
candidiasis, 399
cannabis, 410
carbidopa, 615
carbon dioxide (CO₂)
vasodilation property, 167
carbon monoxide (CO)
poisoning, 375
cardiac abnormalities
complications of stroke,
598–599
cardiac arrest
coronary angiography and
revascularization, 366
critical care approach,
377–378
goal-directed hemodynamic
optimization, 366–367
immediate post-resuscitation
strategies, 366–367
pathophysiology of brain
injury, 364–365
post-cardiac arrest
encephalopathy, 364
prognostication following,
369–372
targeted temperature
management, 366
cardiac conditions
risk of stroke, 580
cardiac emboli
risk evaluation, 105–109
cardiac encephalopathy,
376–377
cardiac evaluation
imaging, 105–109
cardiac myxoma, 173, 332–333
cardiac-origin embolism
anticoagulant indications and
timing, 172–174
cardiac pump failure, 22
cardiac rhythm
ambulatory monitoring, 7
cardiac septal lesions
source of brain emboli,
333–336
cardiac surgery complications
sources of brain emboli,
338–341
cardiac tumors
sources of brain emboli,
332–333
cardiogenic embolism, 66
caregivers
challenges of caring for a
stroke patient, 603
carotid allegro, 387
Carotid and Vertebral
Transluminal
Angioplasty Study
(CAVATAS), 152
carotid arteries
dissections in the neck,
386–389
occlusion, 3, 7
origin of the name, 3
Carotid Occlusion Study, 167
Carotid Occlusion Surgery
Study (COSS), 167, 225
carotid siphon, 26, 36
Carroll, Lewis, 1
cat-scratch disease, 398, 399
catheter angiography, 7
catheter-based mechanical
thrombectomy, 161
catheter digital subtraction
angiography, 104–105
caudate nucleus
infarcts, 241–243
signs and symptoms of ICH,
491
cavernous angiomas, 455–456,
579
diagnosis, 460
imaging findings, 460
locations, 458
of the spine, 539–540
prognosis, 461–462
treatment, 462–464
cavernous sinus thrombosis,
549–551
cavernous sinuses, 33
CBS (cystathionine
beta-synthase) gene
mutation, 131
CDC5 L gene, 137, 138
cellular abnormalities of the
blood, 415
cerebellar vein thrombosis,
549–551, 553
cerebral amyloid angiopathy
(CAA), 38, 104, 302,
395–396
familial forms, 135
microbleeds, 579
risk of ICH, 486
cerebral autosomal dominant
arteriopathy with
subcortical infarcts and
leukoencephalopathy
(CADASIL), 129–130,
288, 302, 419, 512, 513
cerebral autosomal recessive
arteriopathy with
subcortical infarcts and
leukoencephalopathy
(CARASIL), 130–131,
288, 419
cerebral venous sinus
thrombosis
imaging, 97
cerebral venous thrombosis
(CVT), 45
anticoagulant indications and
timing, 174
clinical findings, 547–549
decreased level of
consciousness, 549
definition, 544
demography, 544
development of ideas about,
544
diagnosis, 553–557
distribution of venous
structure involvement,
549–553
dural sinus thrombosis, 544
etiologies, 544–546
abnormalities of the blood
and coagulation system,
546
congenital thrombophilia,
546
hormonal changes, 545
infections, 545
neoplasms, 545–546
pregnancy and
postpartum, 545
systemic conditions, 546
findings related to specific
locations, 549–553
focal neurological signs and
symptoms, 549
frequencies of various causes,
546
headache symptom, 548–549
imaging and neuroradiological
investigations, 553–557
management after the acute
phase, 560
onset and course, 547–548
outcome, 559–560
pathophysiology, 546–547
seizures, 549
treatment, 557–560
cerebellar hemorrhages
signs and symptoms, 497–499
Cerebri Anatome, 3
cerebroretinal vasculopathy
(CRV), 131
cerebrovascular disease
definition, 19
Cervical Artery Dissection
in Stroke Study
(CADISS-NR), 229
Chagas disease, 400
CHANCE trial, 179
Charcot-Bouchard aneurysms,
481
Cheyne, John, 4
children (1 month to 18 years).
See pediatric stroke

Index

- Chinese Intracranial Atherosclerosis Study group, 289
- chronic basal meningitis, 398
- chronic penetrating artery disease
clinical findings, 302
historical background, 301
imaging, 302–303
pathogenesis, 303–304
pathology, 301–302
treatment, 304
- chronic white matter abnormalities
pathogenesis, 303–304
- chronic white matter microbleeds
treatment, 304
- Churchill, Winston, 1
- Churg–Strauss syndrome, 401
- chylomicra, 112, 114
- cilostazol, 169, 177–178
- citicoline, 182
- clopidogrel, 169, 178–179
- Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events (CHARISMA) trial, 179
- Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial, 178
- CLOSURE I trial, 336
- clot retrieval devices, 13, 161, 162–165
- coagulation cascade, 45
- coagulation factors, 112–113
- coagulation system activation, 44–46
- coagulation testing, 112–113
- coarctation of the aorta, 440
- cocaine use, 408–409, 482
and neonatal stroke, 515
ICH related to, 485
stroke related to, 526
- coccidioidal meningitis, 399
- Coccidioides* infection, 398
- Cogan's syndrome, 405
- cognitive defects
therapies for, 617
- cognitive therapies, 617
- Cohorts of Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, 137, 138
- coils
use to obliterate aneurysms, 12
- COL1A1* gene mutations, 136
- COL1A2* gene mutations, 136
- COL3A1* gene mutation, 133
- COL4A1* gene, 139
- COL4A1* gene mutations, 135–136, 288
- COL4A1* syndrome, 131, 135–136, 421
- COL4A2* gene, 139
- cold-pressor test, 482
- collagen vascular diseases, 401–402
- collateral circulation, 3, 19
increasing blood flow in, 167–169
influence on ischemic tissue survival, 46
- color Doppler flow imaging (CDFI), 89–90
- color Doppler imaging, 109
- coma, 367–368
- common carotid arteries (CCAs), 26, 29, 218
- communicating hydrocephalus, 50
- complementary intrinsic coagulation system, 170
- complications of stroke
aspiration, 599–600
brain edema, 595–596
cardiac abnormalities, 598–599
causes of death, 594
challenges for caregivers, 603
contractures, 601
deep vein thrombosis, 597–598
depression, 602–603
fatigue, 602
gastrointestinal bleeding and other complications, 601
immobility and its complications, 601–602
medical complications, 597–600
metabolic disorders, 600
neurological complications, 594–597
nutritional disorders, 600
osteopenia, 601–602
osteoporosis, 601–602
peripheral nerve injuries, 601
pneumonia, 599–600
pressure decubitus ulcers, 601
prevention of complications, 603
psychological effects of stroke, 602–603
pulmonary embolism, 597–598
seizures, 596–597
shoulder pain, 601
stroke progression or recurrence, 594–595
swallowing abnormalities, 599–600
types and frequency, 594
urinary incontinence, 600–601
urinary tract infections, 600–601
- compounded ultrasound imaging, 90
- congenital hemiplegia, 515
- congenital thrombophilia, 546
- congestive heart failure, 546
- congenophilic angiopathy. *See* cerebral amyloid angiopathy (CAA)
- conjugate-gaze paralysis, 72
- connective tissue
heritable disorders, 392–393
- constraint-induced movement therapy (CIMT), 613
- consumptive coagulopathies, 111
- continuous-wave (CW) Doppler, 88–89
- contractures in stroke patients, 601
- Cooperative Study of Intracranial Aneurysms and Subarachnoid Hemorrhage, 440
- Copenhagen City Heart Study, 578
- coronary artery atherosclerosis
risk factor for stroke, 575–576
- coronary artery bypass graft (CABG) surgery
sources of brain emboli, 338–341
- coronary artery disease
source of brain emboli, 331–332
- Coronary Artery Surgery Study (CASS), 331
- cortical vein thrombosis, 549–551, 552–553
- corticosteroids, 187, 399
- cough and cold remedies
ICH risk with phenylpropanolamine (PPA), 485–486
- coumadin, 9, 175
- coumarin, 9
- coxsackie 9 virus, 399
- CREST trial, 152, 223, 228
- critical care management of brain injury
basic critical care, 375–376
neurocritical care, 376
- Crohn's disease, 416, 546
- CRP (C-reactive protein) levels
correlation with stroke risk, 114, 581
- Cruveilhier's atlas, 4
- cryptococcosis, 399
- Cryptococcus* infection, 398
- CRYSTAL AF trial, 320
- CST3* gene mutation, 135
- CT (computed tomography), 7–8
multimodal protocols, 100–101
perfusion imaging, 97, 100–101
scans of vascular lesions, 93
stroke mechanism investigation, 78–79, 80–82
xenon CT, 101
- CT angiography (CTA), 8, 96–97, 217
- CT venography (CTV)
cerebral venous sinus thrombosis, 97
- Cushing response, 480, 598
- Cushing's ulcers, 601
- cyclandelate, 167
- CYP2C9* gene, 172
- cystic medial necrosis, 386
- cysticercosis, 400
- cytoid bodies, 70
- cytomegalovirus, 399
- cytotoxic edema, 47
- dabigatran, 9, 176, 321
- Danaparoid, 174–175
- Danish Aneurysm Study, 441
- Danish Nurse Study, 577
- data banks of stroke data, 8
- Davis, Steven, 6
- D-dimer level measurement, 557
- De Humani Corporis Fabrica, 3
- De Sedibus et Causis Morborum per Anatomen Indagatis, 3
- decompressive hemicraniectomy, 187
- decubitus ulcers, 600, 601
- deep vein thrombosis, 597–598
- deep venous system thrombosis, 549–551, 552
- DEFUSE-2 study, 233
- Dego's disease, 513
- dehydration
thrombosis risk, 546
- Dejong, Russell, 1
- del Zoppo, Gregory, 11
- demographic risk factors for stroke, 569
- depression in stroke patients, 602–603
- desmoteplase, 159, 161
- developmental venous anomalies (DVAs), 455
diagnosis, 460
imaging findings, 460
prognosis, 462
treatment, 462–464
- dexamethasone-suppression test, 602
- diabetes
stroke risk, 573–574, 581
- diabetic ketoacidosis, 399
- diagnosis of stroke, 19
accompanying symptoms, 66
activity at onset, 63
approach to localization, 72
bedside tests of high-level cortical function, 71
common localization patterns, 72–74
comparison with stroke registry or stroke data base information, 74–75
early course of development of the deficit, 63–66
evaluation of motor function, 72

Index

- evaluation of somatosensory functions, 72
evaluation of visual and oculomotor function, 71–72
findings from examination of the eyes, 69–70
findings from examination of the heart, 66
findings from examination of the vascular system, 66–69
history of TIAs, 61–63
identification of the mechanism, 55
inductive method, 56
information used for diagnosis, 55
level of alertness, 71
localization and detection of vascular lesions, 66–70
localization information from the neurological examination, 71
localization of the lesion(s), 55
observation of gait, 72
patient risk factors, 57–60
patient vignette, 55, 59–60, 73–74
pattern-matching technique, 56
prior cerebrovascular symptoms, 61–63
sequential hypothesis generation and testing, 56
technological advances, 7–8
use of Bayes' theorem, 56–57
use of ecological data, 57–60
use of incidence data and probabilities, 56–57
diagnostic tests
 approach to selection of tests, 78
 blood abnormalities and their effects, 110–115
 brain lesion location and characteristics, 82–86
 cause of the brain lesion, 78–82
 genetic testing of stroke patients, 115–116
 identifying seizures in stroke patients, 115
 sequence of diagnostic questions, 78
 stroke mechanism investigation, 78–82
 vascular lesion location and characteristics, 86–110
Diamox (acetazolamide), 168
diaschisis, 103–104, 609
dicumarol, 9
differential diagnosis
 posterior circulation ischemia, 279–280
Diffusion and Perfusion Imaging Evaluation For Understanding Stroke Evolution (DEFUSE) trial, 159
diffusion-perfusion mismatch, 150
diffusion-weighted imaging (DWI), 79
dilatative arteriopathy, 393–395
dipyridamole, 169, 177–178
direct acting oral anticoagulants (DOACs), 115
direct arteriovenous fistulas of the spine, 539–540
direct thrombin inhibitors, 169, 170, 176–177, 321
disseminated intravascular coagulation (DIC), 417, 546
distal protection devices, 151–152
dolichoectasia, 393–395
Donnan, Geoffrey, 6
Doppler, Christian, 86
Doppler sonography systems, 88–93
drowning
 hypoxic brain injury, 374–375
drug abuse vasculopathy, 407–409
 abuse of drugs intended for oral use, 408
 amphetamines, 408
 cocaine use, 408–409
 heroin addiction, 407–408
 infection as a complication of an addictive lifestyle, 408
drug addiction
 infection as a complication of an addictive lifestyle, 408
 risk of infective endocarditis, 326
drug-eluting stents, 154
drug use
 common locations of hemorrhages, 41
 ICH related to, 482, 484–486
 stroke related to, 526
dry edema, 47
dural arteriovenous fistulas of the spine, 538–539
dural arteriovenous malformations (DAVMs), 464–466
dural sinus thrombosis, 544
 anticoagulant indications and timing, 174
Düret, Henri, 5
Duret hemorrhages, 49
dyslipidemia
 risk factor for stroke, 574–575
Eales's disease, 405
echocardiography, 7
EchoPlanar Imaging Thrombolytic Evaluation Trial (EPITHET), 159
eclampsia, 411–412
edema. *See* brain edema
edoxaban, 9, 176, 177, 321
EEG (electroencephalography), 115
 likelihood of seizure in stroke patients, 597
Ehlers–Danlos syndrome, 324, 386, 393, 394, 440
eicosapentaenoic acid, 112, 169
Eisenhower, Dwight D., 2
elevated blood lipids
 risk factor for stroke, 574–575
emboli
 detection and monitoring using TCD ultrasound, 91–92
embolism, 20–22
 definition, 19–20
 distribution of embolic pathology, 38
 recognition of the phenomenon, 3
 See also brain embolism.
embolus protection devices, 151–152
EMBRACE trial, 320
encephalopathy, 328
endarterectomy, 150–151, 217
 risks of carotid endarterectomy, 221–223
endovascular photoacoustic recanalization (EPAR), 344
endovascular treatments
 development of, 12–13
enteroviruses, 399
epidermal growth factor, 616
epidural hemorrhage, 23, 24
Epstein–Barr virus, 417, 418
eptifibatide, 165, 179
erythrocytes
 testing for abnormalities, 110–111
erythropoietin (EPO), 616
ESCAPE Trial, 163
Escourolle, Raymond, 1
essential mixed
 cryoglobulinemia., 418
essential thrombocythemia, 415
état criblé condition, 301, 302
European Carotid Surgery Trial (ECST), 10, 226
European Cooperative Acute Stroke Study (ECASS), 155
European Stroke Prevention Studies (ESPS 1 and ESPS 2), 178
European Stroke Treatment with Ancrod trial (ESTAT), 160
evidence-based medicine, 145
excitotoxin hypothesis, 181–182
exercise
 influence on stroke risk, 578
Extend IA trial, 164
external carotid arteries (ECA), 26–28, 218
external counterpulsation (ECP), 169
extracranial to intracranial (EC–IC) bypass procedures, 10
extracranial vertebral arteries (ECVAs)
 dissections of the ECVA, 259
 occlusion or severe stenosis in the neck, 256–259
 occlusion or severe stenosis of the innominate artery, 252–256
 occlusion or severe stenosis of the subclavian artery, 252–256
 proximal atherosclerotic ECVA disease, 256–259
 subclavian steal syndrome, 252–256
Extremity Constraint Induced Therapy Evaluation (EXCITE) study, 188, 613
Fabrica, 3
Fabry disease, 132, 394, 418–419, 513
factor II, 170
factor V Leiden mutation, 45, 112, 416, 546
factor VIII, 112, 546
factor VIII autoantibodies, 416
factor VIII disorders, 416
factor X, 45, 170
factor Xa, 45
factor Xa inhibitors, 9, 169, 170, 176–177, 321
factor XI, 170
factor XII C46 T gene polymorphism, 546
familial cerebral amyloid angiopathy (CAA), 135
FAST-MAG trial, 158, 165
fat embolism, 347–349
fatigue in stroke patients, 602
FBN1 gene mutation, 133–134
Ferber, Andreas, 11
ferritin
 appearance on MRI, 80
fibrin, 45, 46, 111, 170, 176
fibrin D-dimer testing, 113
fibrinogen, 111–112, 170, 176
 levels correlate with stroke risk, 581
 lowering blood fibrinogen levels, 168–169
fibrinoid degeneration, 288
fibrinolytic system abnormalities, 416
fibromuscular dysplasia (FMD), 20, 386, 391–392, 440
fibrotic valve lesions, 173
Fields, William S., 9–10
Fisher, Charles Miller, 5–7, 9, 13, 184, 217, 287–288, 291
flow-diverting stents, 12

Index

- fluid-attenuated inversion recovery (FLAIR) imaging, 8, 79, 94
Fluoxetine for Motor Recovery After Acute Ischemic Stroke (FLAME) study, 615
fMRI (functional MRI), 109
Foix, Charles, 5
Foix–Alajouanine syndrome, 540
fondaparinux, 177
foreign body embolism, 350–351
Four Score Scale, 443
Framingham Study, 319, 569, 571, 572, 577, 582
free radicals, 42, 43
 damage caused by, 182
fungal causes of vasculitis, 397–399
fungal infection, 551
Furlan, Tony, 11

gait training, 72
Galen, 3
gastrointestinal complications in stroke patients, 601
genetic counseling, 129
genetic factors in stroke, 129
 CADASIL, 129–130
 CARASIL, 130–131
 causes of intracerebral hemorrhage, 135–136
 causes of ischemic stroke, 129–135
 collagen 4A1 (COL4A1) syndrome, 131, 135–136
 disorders linked with stroke risk, 418–421, 581–582
 Fabry disease, 132
 familial cerebral amyloid angiopathy (CAA), 135
 future perspectives, 139–140
 genetic testing of patients, 115–116
 hemoglobinopathies, 131
 hereditary bleeding disorders, 115
 homocystinuria, 131–132
 hypercoagulability conditions, 45, 112
 implications of recent findings, 139–140
 importance in common multifactorial stroke, 136–137
 intracerebral hemorrhage, 137
 Marfan syndrome, 133–134
 MELAS, 134–135
 monogenic disorders causing large artery atherosclerosis and small artery occlusion (lacunar) ischemic stroke, 131–133
 monogenic disorders causing small artery occlusion (lacunar) ischemic stroke, 129–131
 monogenic mitochondrial disorders, 134–135
 osteogenesis imperfecta, 136
 pseudoxanthoma elasticum (PXE), 132–133
 rare single-gene (monogenic) disorders, 129–136
 retinal vasculopathy with cerebral leukodystrophy (RVCL), 131
 risk factors for brain hemorrhage, 139
 risk factors for ischemic stroke, 137–138
 risk factors for stroke, 136–137
 sickle cell disease, 131
 vascular Ehlers–Danlos syndrome (vEDS), 133
genome-wide genotyping, 136–137
geographic location
 influence on stroke risk, 578
Gerstmann syndrome, 276
giant-cell arteritis, 20, 403
giant lacunes, 288
GLA gene mutation, 132
Glasgow Coma Scale, 443
glomus lesions of the spine, 539–540
glutathione peroxidase (GPx-3) gene polymorphisms, 546
glyburide, 187
glycerine, 186
glycerol, 186
glycoprotein (GP) IIb/IIIa antagonists, 179–180
glycoprotein (GP) IIb/IIIa inhibitors, 165
glycosuria
 link with stroke risk, 581
gram-negative bacterial infection, 551
granulocyte-colony stimulating factor (G-CSF), 616
Gronblad–Strandberg disease, 392–393
Grotta, James, 6
growth factor therapies, 616
Gruentzig, Andreas, 12

Hacke, Werner, 11
Hagen–Poiseuille equation, 364
haloperidol, 190, 338
 effect on stroke recovery, 615
hanging
 hypoxic brain injury, 373–374
Harvard Cooperative Stroke Registry, 8
Harvard Stroke Registry, 6, 57–60, 62, 74, 314, 343, 477, 479, 596
HBB (hemoglobin beta) gene mutation, 131
HDAC9 gene, 137, 138

headache and neurological deficits with cerebrospinal fluid lymphocytosis (HaNDL) syndrome, 410
Heart and Estrogen/Progestin Replacement Study (HERS), 577
heart disease
 risk factor for stroke, 572–573
hematocrit
 correlation with stroke risk, 580–581
 measurement, 110–111
 reduction, 168
hematological abnormalities stroke risks, 580
hematological disorders, 414–416
 bleeding disorders, 416
 blood flow disorders, 416–417
 blood viscosity disorders, 416–417
 cellular abnormalities of the blood, 415
 essential thrombocythemia, 415
 hypercoagulability, 416
 leukemia, 415
 paroxysmal nocturnal hemoglobinuria (PNH), 415
 serological disorders, 416
 sickle cell disease, 415
hematological testing, 8
hematomyelia, 540
hemianopia, 275
 therapies for, 617
hemispherectomy, 187
hemimedullary infarction, 261
hemodilution, 168
hemoglobin derivatives
 appearance on MRI, 80
hemoglobinopathies, 111, 131
hemophilia, 416
 acquired form, 416
hemorrhage
 diaschisis, 103–104
 distant regions of metabolic depression, 103–104
 pathology of stroke, 19, 23–24
hemorrhagic fevers, 399
hemorrhagic gastritis, 601
hemorrhagic telangiectasia, 5
hemosiderin, 579
 appearance on MRI, 80
Henoch–Schönlein purpura, 401
heparin, 9, 45, 165, 169, 170
 low-molecular-weight heparins, 170–171
 unfractionated heparin, 170–171
heparin-induced extracorporeal low-density lipoprotein precipitation (HELP), 168–169
heparin-induced thrombocytopenia, 111, 171, 546

heparinoids, 171, 174–175
hepatitis-B antigenemia, 399
hepatitis C virus, 399
hereditary angiopathy with nephropathy, aneurysms, and muscle cramps (HANAC) syndrome, 135, 136
hereditary bleeding disorders, 115
hereditary cerebral hemorrhage with amyloidosis (HCHWA), 135
hereditary endotheliopathy with retinopathy, nephropathy and stroke (HERNS), 131
hereditary hemorrhagic telangiectasia, 420–421
hereditary protein C deficiency, 171
hereditary vascular retinopathy (HRV), 131
heritable disorders of connective tissue, 392–393
herniation of brain tissue, 48–49
heroin addiction, 407–408
Hippocrates, 2–3
Histoplasma infection, 398
historical figures who had strokes, 1–2
history of stroke, 2
 1975 to present, 7–13
 advances in diagnostic technology, 7–8
 Andreas Vesalius, 3
 angiography, 7
 Bright's atlas, 4
 Carswell's atlas, 4
 Charles Foix, 5
 Charles Miller Fisher, 5–7
 Cruveilhier's atlas, 4
 CT (computed tomography), 7–8
 Dark Ages, 3
 data banks, 8
 development of anticoagulant therapies, 9
 development of imaging techniques, 7–8
 development of intensive care units (ICUs), 8–9
 development of stroke units, 8–9
 early twentieth century, 5
 echocardiography, 7
 Egaz Moniz, 7
 eighteenth century, 3–4
 extracranial to intracranial (EC–IC) bypass procedures, 10
 Galen, 3
 Giovanni Battista Morgagni, 3–4
 Hippocrates, 2–3
 Hooper's atlas, 4
 Johann Jakob Wepfer, 3

Index

- John Abercrombie, 4
John Cheyne, 4
mechanical devices, 12–13
mid 20th century, 5–7
Middle Ages, 3
MRI (magnetic resonance imaging), 7–8
nineteenth century, 4–5
nineteenth-century atlases, 4
post-Elizabethan England, 3
randomized clinical trials, 9–11
Rudolph Virchow, 4–5
Sir William Osler, 5
stroke registries, 8
surgical advances, 9–11
Thomas Willis, 3
thrombolysis techniques, 11–12
transcranial Doppler (TCD) ultrasound, 7
ultrasound, 7
histotoxic-hypoxic brain injury, 365
Hodgins, Eric, 1, 2
Hodgkin's disease, 418
Hollenhorst plaques, 69
homocysteine levels
 correlation with stroke risk, 114, 581
homocystinuria, 131–132, 419–420
homolateral ataxia and crural paresis, 293
Honolulu Heart Study, 575
Hooke, Robert, 3
Hooper's atlas, 4
hormonal contraceptives
 stroke risk, 577
hormonal risk factors for stroke, 577–578
hormone replacement therapy
 evaluation of stroke risk, 577–578
Horner's syndrome, 386
HTRA1 gene mutations, 130–131
human immunodeficiency virus (HIV) infection
 stroke risk, 399
Hunt and Hess scale, 443
Hutchinson–Gilford progeria syndrome, 420
hydergine, 167
hydrocephalus
 associated with subarachnoid hemorrhage, 86
 caused by intracerebral hemorrhage, 85
hypercalcemia, 114
hypercoagulability, 44–45, 416
 genetic factors, 112
hyperfibrinogenemia, 417
hyperhomocysteinemia, 419–420
hyperintense acute reperfusion marker (HARM), 94
hyperparathyroidism, 114
hypersensitivity vasculitides, 401
hypertension, 24, 37
 blood pressure lowering targets, 582
 effects on cerebral blood flow, 42
 microbleeds caused by, 579
 risk factor for stroke, 570–572
hypertrophic cardiomyopathy, 324
hypothermia
 neuroprotective potential, 165
hypoxic brain injury, 365
 carbon monoxide (CO) poisoning, 375
 drowning, 374–375
 hanging, 373–374
hypoxic-ischemic brain injury, 364
 anatomy of, 367
 basic critical care, 375–376
 biochemical markers of injury, 371
 borderzone infarcts and hemodynamic impairment, 372–373
 cardiac arrest, 365–367
 cardiac encephalopathy, 376–377
 clinical examination, 369–370
 clinical manifestations, 367–368
 coma, 367–368
 coronary angiography and revascularization, 366
 critical care approach, 377–378
 electrophysiological testing, 370–371
 goal-directed hemodynamic optimization, 366–367
 immediate post-resuscitation strategies, 366–367
 minimally conscious state (MCS), 368
 neurocritical care, 376
 neuroimaging, 368–369, 371
 neurological sequelae, 367–368
 pathophysiology of brain injury, 364–365
 prognostication after cardiac arrest, 369–372
 targeted temperature management, 366
 vegetative state, 368
iatrogenic bleeding disorders, 115
ibuprofen, 177
idiopathic hypertrophic subaortic stenosis, 324
imaging
 cardiac evaluation, 105–109
 catheter digital subtraction angiography, 104–105
 cause of the brain lesion, 78–82
 cerebral venous sinus thrombosis, 97
 comparison between CT and MRI investigations, 80–82
 CT angiography (CTA), 96–97
 CT scans of vascular lesions, 93
 development of imaging techniques, 7–8
 infarcts, 83–84
 intracerebral hemorrhage, 84–85
 MRA of vascular lesions, 95–96
 MRI scans of vascular lesions, 93–94
 multimodal imaging in acute ischemic stroke, 97–101
 newer techniques, 109
 no acute brain lesions found on CT or MRI, 86
 perfusion imaging, 97
 PET scans, 101–104
 sequence of diagnostic questions, 78
 SPECT scanning, 101
 stroke mechanism investigation, 78–82
 subarachnoid hemorrhage (SAH), 85–86
 ultrasound imaging of vascular lesions, 86–93
 vascular lesions in intracerebral hemorrhage, 109
 vascular lesions in subarachnoid hemorrhage, 109–110
 xenon CT, 101
immobility in stroke patients
 complications caused by, 601–602
immunological disorders, 416–417
immunosuppressed patients
 infection risk, 399
 risk of CSF infection, 398–399
increased intracranial pressure, 47, 50
 causes of, 184
 effects of, 184
 reducing or limiting the size of ICH, 184–186
 treatment of brain edema, 186–188
indomethacin, 177
infarction, 23
infarcts
 associated with SAH, 86
 correlating size and location with clinical findings, 84
 diaschisis, 103–104
 distant regions of metabolic depression, 103–104
 establishing the age of, 84
 mass effect caused by, 84
 presence of edema, 84
 presence of other lesions, 84
 size of, 83
 vascular territory involved, 83
infections
 and stroke risk, 416, 581
 role in cerebral venous thrombosis, 545
infectious vasculitides, 397–400
infective endocarditis, 324
 source of brain emboli, 326–328
inflammation
 and blood vessel damage, 581
inflammatory bowel disease, 546
inflammatory disorders
 and stroke risk, 416
innominate arteries
 occlusion or severe stenosis, 252–256
insula of Reil infarction, 237–239
insulin resistance
 risk factor for stroke, 573–574
INTERACT 2 trial, 184
internal capsule
 signs and symptoms of ICH, 487–491
internal carotid arteries (ICA), 26–28
 asymptomatic patients with ICA disease in the neck, 226–228
 atherosclerotic ICA disease in the neck, 217–221
 brain imaging findings in patients with ICA disease, 221–223
 carotid artery clots, 226
 carotid siphon disease, 230–232
 choice of treatment for ICA disease, 221–223
 complete occlusion of the ICA in the neck, 223–225
 dissections in the neck, 386–389
 extracranial carotid artery dissections, 228–230
 intracranial dissections, 233, 390
 intracranial ICA disease, 230–232
 plaque disease of the ICA in the neck with slight or moderate stenosis, 226
 risks of carotid endarterectomy, 221–223
 severe stenosis of the ICA in the neck, 225–226
 sites of atherosclerotic narrowing, 36–37
 top of the carotid artery inclusions, 233
international normalized ratio (INR), 112, 172
International Stroke Genetics Consortium (ISGC), 137, 139

Index

- International Stroke Trial (IST), 173, 174
- International Study of Unruptured Intracranial Aneurysms, 454
- International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT), 545
- intracerebral hemorrhage (ICH), 23, 24
- blood abnormalities, 115
 - clinical course, 477–480
 - decreased level of consciousness, 480
 - detecting vascular lesions, 109
 - diagnosis, 499–500
 - distribution of brain pathology, 41
 - distribution of pathology, 38
 - drainage pathway of the hematoma, 85
 - epidemiology, 477
 - etiologies, 480–486
 - amphetamine use, 484–485
 - bleeding diathesis, 483–484
 - cerebral amyloid angiopathy (CAA), 486
 - cocaine use, 485
 - cough and cold remedies, 485–486
 - drug-induced ICH, 484–486
 - frequencies of common etiologies, 486
 - hypertension, 480–483
 - intravenous use of drugs intended for oral use, 486
 - phenylpropanolamine (PPA), 485–486
 - trauma, 486
 - etiology suggested by the location, 84
 - genetic factors, 135–136, 137, 139
 - headache, 480
 - history of treatment approaches, 477
 - hydrocephalus, 85
 - imaging, 84–85, 109
 - incidence, 439, 477
 - indications of hematoma enlargement, 85
 - mass effect, 84–85
 - pathophysiology, 48–49
 - prognosis, 500
 - reducing or limiting the size of, 184–186
 - seizures, 480
 - signs and symptoms, 477–480
 - signs and symptoms by location, 486–499
 - caudate nucleus, 491
 - cerebellar hemorrhages, 497–499
 - internal capsule, 487–491
 - lateral basal ganglia, 487–491
 - lobar hemorrhages, 492–494
 - pontine hemorrhages, 495–497
 - primary intraventricular hemorrhages, 494–495
 - putamen, 487–491
 - thalamus, 491–492
 - size of the hematoma, 84–85
 - spot sign on CTA images, 85
 - treatment
 - medical treatment, 500–501
 - surgical considerations, 501–504
 - vomiting, 480
- intracranial arterial dissections, 390
- intracranial artery angioplasty/stenting, 153–154
- intracranial branch atheromatous disease, 288–291
- intracranial vertebral arteries (ICVAs)
- ICVA disease, 259–266
- intravascular lymphoma, 417–418
- intravenous magnesium efficacy in stroke (IMAGES), 301
- intraventricular hemorrhage signs and symptoms, 494–495
- ischemia
- causes of brain ischemia, 19–23
 - distribution of brain pathology, 39–40
 - factors affecting tissue survival, 46–47
 - local brain effects, 42–43
 - normal brain metabolism and blood flow, 41–42
 - pathology of stroke, 19–23
 - pathophysiology, 41–44, 46–47
- ischemic penumbra, 43
- ischemic stroke
- blood abnormalities, 110–114
 - genetic risk factors, 137–138
 - multimodal imaging, 97–101
- isoxsuprine, 167
- Joint Study of Extracranial Arterial Occlusions, 9–10
- juvenile lesions of the spine, 539–540
- Kalkar, Jan, 3
- Kawasaki disease, 400
- kidney disease
- link with stroke risk, 581
- Kohlmeier–Degos syndrome, 407
- Korsakoff's syndrome, 277, 373
- Kubik, Charles, 6
- laboratory tests
- cause of the brain lesion, 82
 - lumbar puncture, 82
 - sequence of diagnostic questions, 78
 - stroke mechanism investigation, 82
- lacunar hypothesis, 287
- lacunar infarction, 287
- cognitive impairment, 298
 - diagnostic investigations, 298–299
 - frequency of lacunar stroke, 287
 - general clinical findings, 291–292
 - genetic factors, 129–131
 - hemispherical lesions within the anterior circulation, 292–293
 - imaging findings, 298–299
 - location of lesions and clinical syndromes, 292–298
 - medulla, 293–295
 - midbrain, 295
 - pathogenesis, 303–304
 - pathology, 287–291
 - pons, 293–295
 - posterior circulation, 293–298
 - thalamus, 295–298
 - treatment, 304
- lacunar state, 287
- lacunar stroke
- frequency of, 287
 - treatment, 299–301
- See also chronic penetrating artery disease.
- lacune
- definition, 287
- large artery occlusive disease
- anterior circulation, 217–244
- large artery thrombosis
- anticoagulant indications and timing, 174–176
- large vessel occlusive disease
- posterior circulation, 252–280
- lateral basal ganglia
- signs and symptoms of ICH, 487–491
- lateral sinus thrombosis, 549–552
- Lausanne Stroke Registry, 84, 239, 279–280, 314, 336, 596
- Lemierre syndrome, 400, 545
- Lenin, Vladimir, 1
- leukemia, 111, 415
- leukoaraiosis, 302
- Leukoaraiosis and Disability (LADIS) Study, 302
- leukocytes
- testing for abnormalities, 111
- levodopa, 615
- Libman–Sacks endocarditis, 173, 401
- lipohyalinosis, 287–288, 289, 481
- lipoprotein-associated phospholipase A2 (LpPLA2), 581
- lipoprotein levels in the blood, 112
- Listeria monocytogenes* infection, 398
- lisuride, 189
- livedo reticularis and strokes, 113
- lobar hemorrhages
- signs and symptoms, 492–494
- Locomotor Experience Applied Post-Stroke (LEAPS) trial, 613
- Loeys–Dietz syndrome, 386, 393
- lotrifiban, 179–180
- lovastatin, 184
- lumbar puncture
- stroke mechanism investigation, 82
- lupus anticoagulant (LA), 113, 546
- lupus erythematosus, 173
- lyme borreliosis, 398
- lymphoma, 417–418
- lymphomatoid granulomatosis, 417
- lysergic acid diethylamide (LSD), 485
- lysosomal storage disorders, 132
- macular sparing, 275
- magnesium sulfate, 165
- malaria
- infection of the CNS, 400
- Malayan pit-viper venom extract, 112, 160
- malignant atrophic papulosis, 407
- malignant MCA infarction, 595
- Malpighi, Marcello, 1
- mannitol, 186–187
- marantic non-bacterial thrombotic endocarditis (NBTE), 329–331
- Marfan's syndrome, 133–134, 324, 386, 393, 440, 513
- Marie, Pierre, 287, 292, 301
- mass effect, 22
- brain shift caused by, 48–49
 - caused by infarcts, 84
 - caused by intracerebral hemorrhage, 84–85
 - management, 346
- MATCH trial, 179
- mechanical devices used for stroke interventions, 12–13
- medical complications of stroke, 599–600
- medical figures who had strokes, 1–2
- medulla
- lacunar infarction, 293–295
- MELT trial, 160

Index

- memantine, 615
meningitis, 398, 399
 in endocarditis patients, 328
meningebral hemorrhage, 443
Menkes disease, 419
menopausal hormone
 replacement therapy
 evaluation of stroke risk, 577–578
mental activity therapies, 617
MERCİ retrievers, 162
Merritt, Houston, 1
mescaline, 485
metabolic disorders in stroke patients, 600
metabolic syndrome
 risk factor for stroke, 573–574
methemoglobin
 appearance on MRI, 80
methylphenidate, 408, 486
 therapeutic use, 615
Meyer, John Sterling, 11
Michael Reese Stroke Registry, 57–60, 63, 314, 441, 477, 483
microalbuminuria
 link with stroke risk, 581
microaneurysms, 481
microangiopathy of the brain, ear, and retina, 405–406
microatheromas, 20, 37
microbleeds, 327–328, 395
 appearance on imaging, 579
 imaging, 79–80
 indication of stroke risk, 579
microcirculatory bed
 changes caused by ischemia, 46–47
midbrain
 lacunar infarction, 295
middle cerebral arteries (MCA), 26–28
 atherosclerotic narrowing, 36
 deep infarction of the MCA territory, 236–237
 insula of Reil infarction, 237–239
 intracranial dissections, 390
 mainstream occlusion with total infarction of the MCA territory, 237
 malignant MCA infarction, 595
 occlusion of the inferior division of the MCA, 236
 occlusion or severe stenosis of the MCA stem or its major upper or lower trunks, 233–235
 occlusion or stenosis of the upper division of the MCA, 235
 segmental infarction in the MCA territory, 237
migraine, 168, 218, 386, 387, 409–411
minimally conscious state (MCS), 368
mirror neurons, 617
mitochondrial DNA mutations, 134–135
mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), 134–135, 418, 512
mitral annulus calcification (MAC), 173
 source of brain emboli, 325
mitral valve prolapse (MVP), 173
 source of brain emboli, 324–325
mixed cryoglobulinemia, 401
MMP12 gene, 137, 138
Mohr, Jay P, 6
Moniz, Egaz, 7
Morgagni, Giovanni Battista, 3–4
Mori, Etsuko, 11
movement observation therapies, 617
moyamoya syndrome, 167, 412–414, 511, 512
MR angiography (MRA), 8, 82, 95–96, 217
MR spectroscopy (MRS), 8, 109
MR venography (MRV)
 cerebral venous sinus thrombosis, 97
MRI (magnetic resonance imaging), 7–8
 appearance of hemoglobin derivatives, 80
 fMRI (functional MRI), 109
 multimodal protocols, 97–101
 perfusion imaging, 97
 scans of vascular lesions, 93–94
 stroke mechanism investigation, 79–82
MTHFR deficiency and stroke risk, 114
mucinous adenocarcinoma, 416
Mucor infection, 398–399
multiple myeloma, 112
mumps, 399
mycobacterium tuberculosis, 398
mycoplasma pneumonia infection, 399
mycotic aneurysms, 327–328, 399, 454
myocardial infarction
 source of brain emboli, 331–332
mycardiopathies
 source of brain emboli, 332
nadroparin, 174
NASCET study, 226
nasogastric feeding tubes, 600
National Health and Nutrition Examination Survey (NHANES), 577
neck artery angioplasty/stenting, 151–153
neonatal stroke, 513–516
 arterial and venous strokes, 515–516
 hypoxic-ischemic insults, 513–514
 presumed perinatal ischemic stroke, 515
neoplastic angioendotheliosis, 417
neoplastic disorders
 vasculopathy related to, 417–418
nephrotic syndrome, 546
neurocysticercosis, 511, 525
neurofibromatosis type 1 (NF1), 419, 513
Neuroflo catheter, 169
neurological complications of stroke, 594–597
neurological sequelae of hypoxic-ischemic brain injury, 368
neuroprotection
 increasing the brain's resistance to ischemia, 181–183
 potential of statins, 183–184
neurosphilis, 525
New England Medical Center Posterior Circulation Registry, 254, 256, 257, 263, 266, 279–280
nicotinic acid, 167
nimodipine, 168
NINDS study, 11, 156, 157
NINJ2 gene, 137, 138
nitroglycerin, 165
Nixon, Richard, 2
non-atherosclerotic vasculopathies
 variety of, 386
non-bacterial thrombotic endocarditis (NBTE), 329–331
non-pyramidal hemimotor syndrome, 293
non-steroidal anti-inflammatory drugs, 177
non-thrombotic (marantic) endocarditis, 173
North American Symptomatic Carotid Endarterectomy Trial (NASCET), 10, 224, 582
North Manhattan Stroke Study, 578
Northern Manhattan Study, 291, 581
NOTCH3 gene mutations, 129–130
Nurses Health Study, 577, 578
nutritional disorders in stroke patients, 600
nystagmus, 72
obesity, 332
 risk factor for stroke, 573–574
oculoplethysmography, 109
omega-3 fatty acids, 169
omega-3 fish oil, 112
ophthalmodynamometry, 109
optic ataxia, 278
oral contraceptives
 stroke risk, 45, 416, 577
ORG 10172 174–175
Osler, Sir William, 1, 5
Osler–Weber–Rendu disease, 5, 420–421
osteogenesis imperfecta, 136, 324, 386
osteopenia in stroke patients, 601–602
osteoporosis in stroke patients, 601–602
otitic hydrocephalus, 544
oxygen free radicals, 42, 43
oxyhemoglobin
 appearance on MRI, 80
P-ANCA granulomatosis with polyangiitis, 401
papaverine, 161, 167
paradoxical embolism, 20
 source of brain emboli, 333–336
paramyxovirus, 399
parasitic infections
 as cause of vasculitis, 400
parenchymal hemorrhage, 24
paroxysmal nocturnal hemoglobinuria (PNH), 415, 546
parvovirus, 399
Pasteur, Louis, 1, 567
patent foramen ovale, 20, 173–174
 and stroke risk, 333–336
Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS), 173
pathology of stroke, 19
 damage caused by ischemia, 23
 embolism, 19–22
 epidural hemorrhage, 23, 24
 hemorrhage, 19, 23–24
 infarction, 23
 influence on treatment, 25
 intracerebral hemorrhage (ICH), 23, 24
 ischemia, 19–23
 mechanisms of cerebrovascular damage, 19–24
 parenchymal hemorrhage, 24
 subarachnoid hemorrhage (SAH), 23
 subdural hemorrhage, 23, 24
 systemic hypoperfusion, 19–20, 22
 thrombosis, 19–20
 venous hypertension, 22–23
 venous occlusions, 22–23

Index

- pathophysiology of stroke, 19
arterial occlusion, 43–44
brain shifts and herniations, 48–49
coagulation system activation, 44–46
Duret hemorrhages, 49
factors affecting ischemic tissue survival, 46–47
first three weeks after vascular occlusion, 47–48
increased intracranial pressure, 47
intracerebral hemorrhage (ICH), 48–49
ischemia, 41–44
local brain effects of ischemia, 42–43
normal brain metabolism and blood flow, 41–42
reaction to the occlusive process, 43–44
secondary hemorrhages, 49
subarachnoid hemorrhage (SAH), 50
thrombus formation, 44–46
PDE4D gene polymorphisms, 116
pediatric stroke
approach to diagnosis, 512–513
arterial and venous strokes in neonates, 515–516
clinical presentations and features, 512
compared to adult stroke, 511
differences in evaluation, 526–527
dural sinus and venous occlusions, 521–522
etiological variations related to age, 511
hemorrhagic strokes in children, 517–518
history of recognition and treatment, 517
hypoxic-ischemic insults in neonates, 513–514
incidence, 511, 517
ischemic strokes in children, 518–521
locations of lesions, 511–512
neonatal stroke, 513–516
prevalence of hemorrhagic stroke, 511
prevalence of particular etiologies, 511
prognosis, 513
penetrating artery disease. *See* chronic penetrating artery disease; lacunar infarction; lacunar stroke
pentazocine, 408, 486
pentoxifyllin, 169
Penumbra system, 161
percutaneous endoscopic gastrostomy (PEG) tubes, 600
perfluorochemicals, 169
perfusion imaging, 97, 100–101
perinatal stroke, 511
peripheral nerve injuries in stroke patients, 601
peripheral vascular disease risk factor for stroke, 575–576
Pessin, Michael, 11
PET (positron-emission tomography), 101–104
petrosal sinuses, 33, 34
PHACTR1 gene, 138
PHANTOM-S trial, 158
pharmacological agents which retard recovery, 615
pharmacological therapies to enhance recovery, 615
phencyclidine (PCP, angel dust) as cause of ICH, 485
phenylbutazone, 177
phenylephrine, 150, 486
phenylpropanolamine (PPA) risk of ICH, 485–486
phlebothromboses, 45
phosphodiesterase inhibitors, 167, 177–178
Physicians Health Study, 571, 578
PITX2 gene, 137–138
plasmapheresis techniques, 168–169
plasmin, 45, 154
plasminogen, 45
plasminogen deficiency, 546
Plasmodium falciparum infection of the CNS, 400
platelet function modifiers
antiplatelet therapies for specific vessel sites, 180
aspirin, 177
cilostazol, 177–178
clopidogrel, 178–179
dipyridamole, 177–178
GP IIb/IIIa antagonists, 179–180
phosphodiesterase inhibitors, 177–178
thienopyridines, 178–179
ticlopidine, 178–179
platelets
testing for abnormalities, 111
PMF1 gene, 137, 139
pneumococcal infection, 551
pneumonia
complication in stroke patients, 599–600
Poeck, Klaus, 11
POINT trial, 179
polyarteritis nodosa, 399, 401
polycystic kidney disease, 440
polycythemia, 170, 415, 417
polycythemia vera, 546
polypharmacy in stroke patients, 190, 615
pons
lacunar infarction, 293–295
pontine hemorrhage
signs and symptoms, 495–497
post-cardiac arrest encephalopathy. *See* cardiac arrest; hypoxic-ischemic brain injury
posterior cerebral arteries (PCA), 26–28, 31, 244
intracranial dissections, 390
occlusion or severe stenosis, 273–275
cognitive and behavioral abnormalities, 276–277
motor abnormalities, 275–276
somatosensory abnormalities, 275
upper and lower calcarine bank lesions, 277–279
visual field abnormalities, 275
posterior circulation, 28–29
large vessel occlusive disease, 252–280
posterior circulation ischemia differential diagnosis, 279–280
posterior inferior cerebellar arteries (PICAs), 31
posterior reversible encephalopathy syndrome (PRES), 411–412
postpartum angiopathy, 409
postpartum cerebral venous thrombosis (CVT), 545
postpartum risk of stroke, 577
power Doppler, 89–90
prasugrel, 169
pravastatin, 184
praziquantel, 400
preeclampsia/eclampsia, 411–412
pregnancy
risk of cerebral venous thrombosis (CVT), 545
risk of stroke, 577
Premarin, 577
prevention of stroke
abdominal imaging, 579
alcohol risk factor, 575
aortic conditions, 580
benefits of exercise, 578
biomarkers for vascular disease, 580–581
blood pressure lowering targets, 582
cardiac conditions, 580
cervico-cranial and intracranial arterial abnormalities, 580
coronary artery atherosclerosis risk factor, 575–576
demographic risk factors that are not modifiable, 569
diabetes risk factor, 573–574
dyslipidemia risk factor, 574–575
effects of hormone replacement therapy, 577–578
evaluation of stroke risk, 568–569
future developments, 583
genetic conditions related to vascular disease, 581–582
heart disease risk factor, 572–573
hematological abnormalities, 580
high stroke-mortality regional clusters, 578
hormonal risk factors, 577–578
hypertension risk factor, 570–572
identifying people at risk, 582
importance of beginning at an early age, 569–570
importance of prevention, 567
influence of geographic location, 578
insulin resistance risk factor, 573–574
metabolic syndrome risk factor, 573–574
obesity risk factor, 573–574
oral/hormonal contraceptive use risk factor, 577
peripheral vascular disease risk factor, 575–576
pregnancy and postpartum risk of stroke, 577
presence of brain microbleeds, 579
presence of unexpected brain infarcts, 578–579
presence of white matter lesions, 579
prevention strategies, 567–569
primary prevention, 582
public education, 567, 582
retinal examination, 579
risk associated with sedentary lifestyle, 578
risk factors for stroke, 569–578
secondary (recurrent) prevention, 582–583
silent strokes, 578–579
smoking risk factor, 574
statin therapy, 183–184, 582
subclinical cardio-cervico-cranial hematological lesions, 579
subclinical indications of vascular disease and vascular risks, 578–580
transient ischemic attack (TIA) risk factor, 576–577

Index

- Prevention Regimen For
Effectively avoiding
Second Strokes
(PROFESS) trial, 300
primary angiitis of the CNS
(PACNS), 403–404
PRKCH gene, 138
progeria, 420
prognostic scoring, 61
prognostication after cardiac
arrest, 369–372
programmed cell death
(apoptosis), 43
Prolyse in Acute Cerebral
Thromboembolism
(ProACT) trials, 156,
160
prophylactic treatment to
prevent reembolization,
346–347
prosopagnosia, 277
prosthetic cardiac valves
source of brain emboli,
325–326
protein, 45
protein C, 45, 112
protein C deficiency, 171, 416
protein S, 112
protein S deficiency, 416
proteinuria
link with stroke risk, 581
prothrombin, 45, 170
prothrombin *G20210A*
mutation, 546
prothrombin gene mutation,
112, 416
prothrombin time (PT), 112
pro-urokinase, 11
Provera, 577
pseudo-heritability of stroke,
136–137
pseudomigraine syndrome with
temporary neurological
symptoms and lympho-
cytic pleocytosis (PMP
syndrome), 410
pseudo-tumor syndrome, 558
pseudoxanthoma elasticum
(PXE), 132–133,
392–393, 440
psychological effects of stroke,
602–603
public education about stroke
risk factors, 567, 582
puerperal dural sinus
thrombosis, 544
pulmonary embolism, 364,
597–598
pulsed-Doppler system, 88–89
pulseless disease (Takayasu's
arteritis), 404
pure motor hemiplegia, 292
Purtillo syndrome, 418
putamen
signs and symptoms of ICH,
487–491
pyribenzamine, 408, 486
quantitative magnetic resonance
angiography (QMRA),
96
Quinke, H., 544
randomized clinical trials, 9–11,
145
Randomized Trial of Tirilazad
Mesylate in Acute
Stroke, 594
Reasons for Geographical and
Racial Differences in
Stroke (REGARDS)
study, 578, 579
recovery after stroke, 608–609
strategies to promote
recovery, 188–190
See also brain repair
strategies.
red thrombi, 43–44, 45, 111,
168, 169–170, 174, 176
REduction of Atherothrombosis
for Continued Health
(REACH) registry, 575
rehabilitation after stroke,
609–610
coordination of acute and
long-term care, 612–613
functioning in rehabilitation
units, 610–612
relapsing polychondritis,
402–403
renal failure, 399
repair. *See* brain repair strategies
reperfusion injury, 365
resistance to activated protein C,
112
resistance to protein C, 112
retinal examination, 579
retinal vasculopathy with
cerebral leukodystrophy
(RVCL), 131, 513
retino-cochleo-cerebral
vasculopathy, 405–406
reversible cerebral vasoconstric-
tion syndrome (RCVS),
396, 403, 486
Reykjavik (Iceland) study, 578
rheumatic mitral valve disease
source of brain emboli,
322–323
rheumatic valvulitis, 324
rheumatoid arthritis, 402
rhinocerebral mucormycosis,
399
Ringelstein, Berndt, 11
risk factors for stroke, 569–578
alcohol use, 575
coronary artery atherosclero-
sis, 575–576
demographic factors that are
not modifiable, 569
diabetes, 573–574
dyslipidemia, 574–575
elevated blood lipids, 574–575
geographic location, 578
heart disease, 572–573
hormonal risk factors,
577–578
hypertension, 570–572
importance of beginning
prevention at an early
age, 569–570
insulin resistance, 573–574
lack of physical exercise, 578
menopausal hormone
replacement therapy,
577–578
metabolic syndrome,
573–574
obesity, 573–574
oral/hormonal contraceptive
use, 577
peripheral vascular disease,
575–576
pregnancy and postpartum,
577
sedentary lifestyle, 578
smoking, 574
transient ischemic attacks
(TIAs), 576–577
Risk of Paradoxical Embolism
(RoPE) score, 336
Ritalin, 408
rivaroxaban, 9, 176, 177, 321
RNF213 gene polymorphisms,
414
robot-based therapies, 613–614
Roosevelt, Franklin D., 1
rt-PA (recombinant tissue
plasminogen activator),
154–155, 157, 165, 416
sagittal sinus thrombosis,
549–551
sarcoidosis, 402, 546
scleroderma, 402
scotoma, 617
Secondary Prevention of Small
Subcortical Strokes
(SPS 3) trial, 180
sedentary lifestyle
risk factor for stroke, 578
segmental arterial disorganiza-
tion, 288
Seizures after Stroke Study, 596
seizures in stroke patients
complication of stroke,
596–597
EEG (electroencephalogra-
phy), 115
Seldinger, SI, 7
SEMA4A gene, 139
senile marantic venous sinus
thrombosis, 546
sensory stimulation therapies,
614
sentinel headache, 57, 441
septic arteritis, 399
Serbenenko, FA, 12
serine protease coagulation fac-
tors, 416
serological disorders, 416
serological factors
influence on ischemic tissue
survival, 46
serotonin, 168
serotonin reuptake inhibitors,
410
serum albumin and globulin
levels, 112
serum sickness, 401
SH2B3 gene, 138
Sharon, Ariel, 2
Shaw, George Bernard, 145
shoulder-hand syndrome, 601
shoulder pain in stroke patients,
601
sick sinus syndrome, 322
sickle cell disease, 111, 131, 394,
415, 546
sickle cell hemoglobin C disease,
415
sigmoid sinuses, 33
sildenafil (Viagra), 486
silent strokes, 19
simultanagnosia, 278
simvastatin, 184, 568
single subcortical infarcts, 289
sinoatrial disorder, 322
sinus node dysfunction, 322
Sjögren's syndrome, 402, 546
SLC25A4 gene, 137
SLC25A44 gene, 139
smoking
effects on WBC count, 581
risk factor for stroke, 574
Sneddon's syndrome, 113,
406–407
Solitaire With the Intention For
Thrombectomy
(SWIFT) trial, 162
SPACE trial, 152
sparganosis, 400
SPECT (single-photon-emission
computed tomography),
101
sphenoid sinusitis, 400
spherocytosis, 111
spinal cord
arterial circulation, 534–535
borderzone (watershed)
region, 535
clinician's approach to spinal
lesions, 534
ischemia and infarctions,
536–538
localization of spinal lesions,
534
unique clinical-anatomical
correlations, 534
vascular disease and stroke,
534
vascular system, 534–536
venous circulation, 535–536
spinal dural arteriovenous
fistulas, 538–539
spinal hemorrhages, 540
spinal transient ischemic
attacks (TIAs), 536,
538–539

Index

- spinal vascular malformations, 538–540
dural (type I), 538–539
intradural (type II), 539–540
- spine
cavernous angioma, 539–540
direct arteriovenous fistulas, 539–540
glomus lesions, 539–540
juvenile lesions, 539–540
- Stalin, Joseph, 1
- Staphylococcus aureus* acute endocarditis, 328
- Staphylococcus aureus* infection, 551
- statins, 568, 582
role in stroke prevention and treatment, 183–184
- stem cell therapies, 615–616
- stem cell transplantation, 188
- stent retrievers, 162, 163–165
- stenting, 151–154, 161, 217
- Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial, 153, 232, 266
- Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) study, 152
- Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA) trial, 259
- stents, 12–13
- STICH 1 trial, 185
- Stopford, JS, 5
- straight sinus thrombosis, 549–551
- streptococcal infection, 551
- Streptococcus pneumoniae*, 114
- streptokinase, 11, 154, 155, 160
- stress ulcers, 601
- stroke
annual worldwide mortality rates, 1
as model of brain and vascular disease, 13
costs of, 1
definition, 19
disability caused by, 1
heterogeneous nature, 19
in historical and medical figures, 1–2
incidence worldwide, 1
personal tragedy of, 2
stroke belt phenomenon, 578
stroke care, 13
stroke centers, 149
delivery of patients to, 157–158
development of competent centers, 157–158
Stroke Data Bank, 314, 336, 477
- stroke-like migraine attacks
after radiation therapy (SMART) syndrome, 410–411
- stroke mechanism
comparison between CT and MRI investigations, 80–82
CT investigation, 78–79
lumbar puncture investigation, 82
MRI investigation, 79–80
- stroke nurses, 8–9
- Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) study, 301
- Stroke Prevention in Reversible Ischemia Trial (SPIRIT), 172
- stroke progression or recurrence, 594–595
- stroke registries, 8
- stroke risk-factor score, 582
- stroke specialists, 8–9
- Stroke Treatment with Ancrod Trial (STAT), 160
- stroke units, 8–9, 149
- Study of Prevention of Small Subcortical Strokes (SPS3) trial, 300
- Subacute Therapy with Amphetamine and Rehabilitation for Stroke (STARS) study, 615
- subarachnoid hemorrhage (SAH), 23, 168
arteriovenous malformations (AVMs), 454–455
assessing the extent of bleeding, 85–86
blood abnormalities, 115
causes, 439
convexal subarachnoid hemorrhage, 85
CT findings, 79
distribution of pathology, 38–39
hydrocephalus, 86
imaging, 85–86
imaging of vascular lesions, 109–110
incidence, 439
location of the blood, 85
lumbar puncture investigation, 82
magnetic resonance imaging (MRI), 80
pathophysiology, 50
regions of infarction, 86
spinal, 540
symptoms, 439
See also aneurysmal SAH.
- subclavian arteries, 29
occlusion or severe stenosis, 252–256
- subclavian steal syndrome, 252–256
- subcortical arteriosclerotic encephalopathy, 301
- subdural hemorrhage, 23, 24
- suction thrombectomy, 161–162
- superior cerebellar artery (SCA), 31
- superior sagittal sinuses, 33
- surgical advances, 9–11
- surgical endarterectomy, 150–151
- Susac syndrome, 405–406, 512, 513
- susceptibility-weighted imaging (SWI), 79–80
- swallowing abnormalities in stroke patients, 599–600
- SWIFT PRIME trial, 164
- Symonds, Sir Charles, 544
- synthetic heparin
pentasaccharides, 171
- synthetic pentasaccharides, 170
- syphilis, 324, 398
- syphilis testing, 113
- systemic circulation
influence on ischemic tissue survival, 46
- systemic hypoperfusion, 22
definition, 19–20
- systemic hypotension, 22
- systemic lupus erythematosus (SLE), 111, 328–331, 401, 513, 546
- systemic sclerosis, 402
- systemic vasculitides, 401–402
- Systolic Hypertension in the Elderly Program (SHEP), 571
- tadalafil (Cialis), 486
- Takayasu's arteritis, 20, 114, 404
- takotsubo cardiomyopathy, 332
- Talwin, 408
- telangiectases (telangiectasias), 456
- telerehabilitation, 614
- temporal arteritis, 37, 114, 403
- tenecteplase, 161
- Terson's syndrome, 442
- thalamus
lacunar infarction, 295–298
signs and symptoms of ICH, 491–492
- Thibault, George, 145
- thienopyridines, 178–179
- Thrombectomy
REvascularization of large Vessel Occlusions in acute ischemic stroke (TREVO) 2 trial, 162
- thrombi
prevention of formation and propagation, 169–170
- thrombin, 45, 111, 170
- thrombin inhibitors, 9, 176–177
- thromboangiitis obliterans, 404
- thrombocytopenia, 113, 415
- heparin induced, 171
- thrombocytosis, 111, 170, 546
- thrombolysis, 97–99, 154–157
development of techniques, 11–12
early observational studies, 154–155
early studies, 154
effects of FDA approval of rt-PA, 157
improving IV thrombolysis, 160
multiple neuroprotective and thrombolytic combinations, 165
potential benefits of TCD monitoring, 165–166
present recommendations for, 166–167
randomized trials of IA thrombolysis, 156–157
randomized trials of IV thrombolysis, 155–156
rationale for, 154
selection of candidates for, 159–160
- thrombolytics, 160–161
ancrod, 160
desmoteplase, 161
rt-PA, 154–155, 157
streptokinase, 154, 155, 160
tenecteplase, 161
urokinases, 155, 160
- thrombosis, 20
definition, 19–20
distribution of pathology, 36–38
- thrombosis pathophysiology
adequacy of collateral circulation, 46
brain edema, 47
changes within the obstructing vascular lesion, 46
factors affecting tissue survival, 46–47
first three weeks after vascular occlusion, 47–48
increased intracranial pressure, 47
resistance within the microcirculatory bed, 46–47
serological factors, 46
state of the systemic circulation, 46
thrombus formation, 44–46
- thrombotic thrombocytopenic purpura (TTP), 111, 401–402
- ticlopidine, 169, 178–179
- Ticlopidine–Aspirin Stroke Study (TASS), 178
- tirofiban, 165, 179
- tPA (tissue plasminogen activator), 45, 46, 157, 165
- transcranial direct current stimulation (tDCS), 189, 615

- transcranial Doppler (TCD)
ultrasound, 7, 90–91,
312
embolus detection and
monitoring, 91–92
studying cranial venous
structures, 93
to enhance perfusion,
165–166
transcranial magnetic stimulation
(TMS), 189, 614–615
transesophageal echocardiogra-
phy (TEE), 8, 105–108
transient cerebral arteriopathy,
512
transient ischemic attacks
(TIAs), 3, 6, 217, 218,
387–388
diagnostic and prognostic
features, 61–63
magnetic resonance imaging
(MRI), 81–82
risk factor for stroke, 576–577
spinal TIAs, 536, 538–539
transplant patients
CSF infection risk, 398–399
transthoracic echocardiography
(TTE), 105–106
transverse sinuses, 33
traumatic intracerebral
hemorrhage (ICH), 486
treatment
coordination of acute and
long-term care, 612–613
treatment of ischemic stroke,
149–184
angioplasty and/or stenting,
151–154, 161
anticoagulants, 170–177
antiplatelet therapies for
specific vessel sites, 180
approach to treatment, 149
catheter-based mechanical
thrombectomy, 161,
162–163
clinician approach to
treatment, 190
clot retrieval devices, 161,
162–165
comments and rules for
clinicians, 190
controlling position and
activity, 149–150
improving IV thrombolysis,
160
increasing blood flow in the
collateral circulation,
167–169
increasing perfusion in the
ischemic-zone capillary
bed, 167–169
increasing the brain's
resistance to ischemia,
181–183
intracranial artery angio-
plasty/stenting, 153–154
local reconstruction, 150–151
managing blood pressure, 150
managing blood volume, 150
managing cardiac output, 150
maximizing blood flow,
149–150
multiple neuroprotective
and thrombolytic com-
binations, 165
neck artery angioplasty/
stenting, 151–153
neuroprotection potential of
statins, 183–184
neuroprotection strategies,
181–183
platelet function modifiers,
177–180
present recommendations for
thrombolysis, 166–167
prevention of clot formation,
propagation and
embolism, 169–170
promoting recovery, 188–190
range of endovascular
mechanical interventions,
161
reducing blood viscosity,
168–169
reperfusion strategies, 150–157
reperfusion using mechanical
techniques, 161–165
reperfusion using multiple
techniques, 165
selection of candidates for
thrombolysis, 159–160
strategies for earlier
treatment, 158
suction thrombectomy,
161–162
surgical endarterectomy,
150–151
surgically bypassing regions
of blockage, 167
thrombolysis, 154–157, 160,
166–167
thrombolytics other than
rt-PA, 160–161
use of ultrasound to enhance
perfusion, 165–166
use of vasodilating agents,
167–168
volume expansion, 168
treatment of stroke, 19
approach to treatment, 145
control of brain edema,
186–188
control of increased intracra-
nial pressure, 186–188
delivery of patients to stroke
centers, 157–158
development of competent
medical centers,
157–158
door-to-needle time, 157–158
evidence-based medicine, 145
general care, 148–149
influence of stroke
mechanism, 25
reducing or limiting the size
of ICH, 184–186
results from randomized
clinical trials, 145
stroke centers, 149
stroke units, 149
treatment planning
availability of personnel and
technology, 147
blood abnormalities, 146
characteristics of the brain
lesion, 146–147
general therapeutic strategies,
147
hematological disorders, 146
mechanisms and pathophy-
siology of stroke, 146
nature of the vascular lesion,
146
pace of the stroke, 147
presence of other medical
conditions, 146
psychological factors, 146
reasons for worsening in
stroke patients, 146–147
reversibility of the brain
lesions, 146–147
risk for further ischemia,
146–147
socioeconomic factors, 146
specific problems in
individual patients, 147
TREX1 gene mutations, 131
Trial of ORG 10172 in Acute
Stroke Treatment
(TOAST), 174
trifusal, 169
trigeminal nerve stimulation
association with ICH, 482
Trypanosoma cruzi infection,
400
tuberculous meningitis, 398, 511
tumor embolism, 350
ulcerative colitis, 416, 546
ultrasound, 7, 8, 217
use to enhance perfusion,
165–166
ultrasound imaging
brightness modulation
(B-mode) ultrasound,
87–88
development of, 86–87
Doppler sonography systems,
88–93
University of Illinois Stroke
Registry, 441
urinary incontinence in stroke
patients, 600–601
urinary tract infections in stroke
patients, 600–601
urokinases, 155, 160, 165
vasculopathy
neoplastic disorders, 417–418
vampire bat saliva enzyme, 159
vardenafil (Levitra), 486
varicella-zoster virus (VZV)
angiopathy, 399
vasa vasorum, 31
vascular Ehlers–Danlos
syndrome (vEDS), 133
vascular endothelial growth
factor (VEGF), 616
vascular lesions
cardiac embolus risk
evaluation, 105–109
cardiogenic embolism, 66
catheter digital subtraction
angiography, 104–105
CT angiography (CTA),
96–97
CT scans, 93
findings from examination of
the eyes, 69–70
findings from examination of
the heart, 66
findings from examination of
the vascular system,
66–69
general and neurological
examination, 66–70
imaging cerebral venous
sinus thrombosis, 97
imaging in intracerebral
hemorrhage, 109
imaging in subarachnoid
hemorrhage, 109–110
localization and detection,
66–70
MR angiography (MRA),
95–96
MRI scans, 93–94
multimodal imaging, 97–101
newer imaging techniques,
109
perfusion imaging, 97
PET scans, 101–104
SPECT scanning, 101
tests to identify location and
characteristics, 86–110
ultrasound imaging, 86–93
xenon CT, 101
vascular malformations,
454–455
arteriovenous malformations
(AVMs), 455
cavernous angiomas, 455–456
classification, 455
clinical symptoms and signs,
458–460
developmental venous
anomalies (DVAs), 455
diagnosis, 460
dural arteriovenous
malformations
(DAVMs), 464–466
endovascular treatment, 463
etiologies, 455
imaging findings, 460
location of the various
malformations, 458
medical treatment, 464
pathogenesis of AVMs,
456–457
prognosis for AVMs, 461
prognosis for cavernous
angiomas, 461–462

Index

- prognosis for developmental venous anomalies (DVAs), 462
- radiotherapy, 463
- surgical treatment, 462–463
- telangiectases (telangiectasias), 456
- treatment, 462–464
- vasculitis
 - as cause of stroke, 396
 - bacterial infections, 397–399
 - caused by infections, 397–400
 - fungal infections, 397–399
 - parasitic infections, 400
 - systemic vasculitides, 401–402
 - viral infections, 399–400
- vasculopathy
 - caused by drug abuse, 407–409
- vasoconstriction syndromes, 409–411
- vasodilating agents, 167–168
- vasogenic edema, 47
- vegetative state, 368
- vein of Galen, 34
- veins of Labbé, 22, 34
- veins of Rosenthal, 34
- veins of Trolard, 34
- venous and dural sinus anatomy, 31–34
- venous hypertension, 22–23
- venous occlusions, 22–23
- venous stasis retinopathy, 219, 579
- vertebral arteries, 28–31
 - dissections in the neck, 389–390
 - intracranial dissections, 390
 - See also* extracranial vertebral arteries; intracranial vertebral arteries.
- vertebrobasilar disease, 252
- Vesalius, Andreas, 3
- viral causes of vasculitis, 399–400
- Virchow, Rudolph, 4–5
- VISSIT trial, 154
- visual field abnormalities, 275
 - transient blindness, 218, 231
- visual field defects
 - therapies for, 617
- visual neglect, 275, 277
- vitamin K, 45
- VKORC1 gene, 172
- Vogt–Koyanagi–Harada syndrome, 406
- von Willebrand disease, 416
- Waldenström’s macroglobulinemia, 112, 417
- warfarin, 9, 45, 115, 169, 170, 171, 172, 174, 177, 320–321
- Warfarin Aspirin Recurrent Stroke Study (WARSS), 9, 173, 175, 300
- Warfarin–Aspirin for Symptomatic Intracranial Disease (WASID) trial, 9, 175, 176, 180, 232, 239, 266, 581
- watershed regions, 22, 39–40
 - spinal cord, 535
- Weber’s syndrome, 295, 441
- Wegener’s granulomatosis, 401, 546
- Wepfer, Johann Jakob, 3
- wet edema, 47
- white blood cell (WBC) count, 111
 - correlation with stroke risk, 581
- white clots, 43–44, 46, 70, 111, 168, 169–170
- Willis, Thomas, 3
- Wilson, Woodrow, 1
- Women’s Estrogen Stroke Trial (WEST), 577
- Women’s Health Initiative (WHI), 577
- Women’s Health Initiative Memory Study in Younger Women (WHIMSY), 577
- Women’s Health Study, 575
- World Federation of Neurological Surgeons Scale (WFNS), 443
- World Health Organization (WHO) international Classification of Functioning, Disability, and Health (ICF), 609–610
- Wren, Christopher, 3
- xenon CT, 101
- ximelagatran, 176
- X-linked lymphoproliferative disease (XLP), 418
- Yasargil, Gazi, 10
- young adult stroke
 - approach to diagnosis, 512–513
 - clinical presentations and features, 512
 - clues for specific etiologies, 522–526
 - compared to older adult stroke, 511
 - differences in evaluation, 526–527
 - etiological variations related to age, 511
 - incidence, 511
 - locations of lesions, 511–512
 - prevalence of hemorrhagic stroke, 511
 - prevalence of particular etiologies, 511
 - prognosis, 513
 - studies, 522
- Zeumer, Hermann, 11
- ZFH3 gene, 137–138